Article Text

This article has a correction. Please see:

PDF
Role of the clinical pharmacist in a paediatric haemato-oncology stem cell transplantation ward
  1. Tiene Bauters1,
  2. Joan Vinent-Genestar2,
  3. Judith Delaney3,
  4. Julie Mycroft4,
  5. Johan Vandenbroucke1
  1. 1Department of Pharmacy, Ghent University Hospital, Ghent, Belgium
  2. 2Department of Pharmacy, Sant Joan de Déu Hospital, Barcelona, Spain
  3. 3Department of Haematology/Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
  4. 4Department of Paediatric Oncology, Royal Marsden NHS Foundation Trust, Surrey, UK
  1. Correspondence to Dr Tiene Bauters, Department of Pharmacy, Ghent University Hospital, -1 K12, De Pintelaan 185, Ghent B-9000, Belgium; tiene.bauters{at}uzgent.be

Abstract

The number of haematopoietic stem cell transplantations (HSCT) in children has expanded in the last decades and still continues to increase. To ensure safe and effective care in this vulnerable high-risk population, treatment should be undertaken in a specialist unit by an experienced and fully dedicated multidisciplinary team. HSCT pharmacists are well-positioned to take a lead role in patient assessment and the development and implementation of guidelines for supportive care. This article aims to summarise the sparse literature data on clinical pharmacy activities in the paediatric HSCT setting augmented with advice from expert opinion. Many of these patients require routine management for immunosuppression or complications related to HSCT. Clinical activities for pharmacists include participation in ward rounds (where drug-related problems are discussed with physicians and nurses) and analysis of drug-related problems (eg, untreated indication, subtherapeutic or supratherapeutic dosages, non-conformity to hospital guidelines, therapeutic drug monitoring of immune suppressives or antibiotics, monitoring for drug–drug or drug–food interactions, detection of adverse reactions or problems with administration of intravenous drugs) and counselling on discharge medication. In addition, the pharmacist's role in the development and implementation of guidelines on acute effects or toxicities (mucositis, chemotherapy-induced nausea and vomiting, graft-vs-host disease, bacterial, viral and fungal infections) and late effects or toxicities (chronic graft-vs-host disease) are discussed.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Corrections
    British Medical Journal Publishing Group